SLC5A2 and metabolic dysfunction-associated steatotic liver disease: There is now an emerging body of evidence suggesting that GLP-1RA and SGLT2 inhibitors have a beneficial impact in NAFLD, whereas DPP-IV inhibitors seem to have a near-null effect [[28], [29], [30]].